ASRS 2024: Retinal vascular changes in patients with Alzheimer's Disease
July 28th 2024Sruthi Arepalli, MD, spoke about her presentation, "Assessing retinal vascular changes in Alzheimer's disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Novel approach to myopic traction maculopathy
July 27th 2024Nikoloz Labauri, MD, FVRS, founder of DAVINCI Eye Clinic in Tbilisi, Georgia, discusses his presentation, "Suspensory Macular Buckling for Myopic Traction Maculopathy" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden
ASRS 2024: Results of the LIGHTSITE III study
July 26th 2024Eleonora Lad, MD, PhD, spoke about her presentation, "Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of geographic atrophy in dry age-related macular degeneration" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.
ASRS 2024: Intraoperative fluorescein angiography improving outcomes in diabetic vitrectomy
July 25th 2024Alan Franklin, MD, PhD, FASRS, spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.
ASRS 2024: Socioeconomic barriers and visual outcomes
July 24th 2024Sally S. Ong, MD, spoke about her study on the impact of individual and neighborhood-level social determinants of health on vision and foveal status at presentation in patients with rhegmatogenous retinal detachments at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Long-term results of using indocyanine green to peel internal lining membrane
July 24th 2024John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Characterization of HK1 mutations and retinitis pigmentosa
July 23rd 2024Patrick C. Staropoli, MD, discussed his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa while attending the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Real-world safety and efficacy of aflibercept 8 mg in the treatment of nAMD
July 20th 2024Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Neurotech Pharmaceuticals update on the NT-501 device
July 19th 2024Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Illuminating subclinical sickle cell activities using dynamic OCT angiography
July 19th 2024Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Diabetic retinopathy lesion types and distribution on ultra-widefield imaging
July 19th 2024Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: IOP outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma
July 19th 2024Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: New data for Susvimo demonstrates sustained efficacy in DME, DR
July 18th 2024The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.
ASRS 2024: Results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
July 18th 2024Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Fas inhibition with ONL1204 for the treatment of geographic atrophy
July 18th 2024Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: 72-Week results from phase 3 BALATON and COMINO trials
July 18th 2024Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.